Skip to main content
SpringerLink
Log in

Practical Aspects of Obesity Treatments

Combination Therapies

  • Chapter
The Management of Eating Disorders and Obesity

Part of the book series: Nutrition ◊ and ◊ Health ((NH))

  • 203 Accesses

Abstract

With the realization that obesity is a disease not a psychological problem, the horizons of obesity treatment have widened. The concept of drug treatment of obesity has gained more widespread acceptance, and the most recent and exciting developments in obesity treatment have involved the use of drugs as an integral component. This chapter will review the concept of obesity as a disease and discuss the integration of the standard treatment of obesity, including diet, exercise (see Chapter 13), and behavior modification (see Chapter 14), with single drugs or combinations of drugs, as a potentially more effective regimen for the long-term maintenance of weight loss (Table 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chagnon YC, Perusse L, Bouchard C. The human obesity gene map the 1997 update. Obesity Res 1998; 6: 76–92.

    Article  CAS  Google Scholar 

  2. Kuczmarski RI, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. JAMA 1994; 272: 205–211.

    Article  CAS  Google Scholar 

  3. Kuczmarski RJ, Carroll MD, Flegal KM, Troiano RP. Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994). Obesity Res 1997; 5: 542–548.

    Article  CAS  Google Scholar 

  4. Andersen T, Stokholm KH, Backer OG, Quaade F. Long-term (5-year) results after either horizontal gastroplasty or very-low calorie diet for morbid obesity. Int J Obes 1988; 12: 277–284.

    CAS  Google Scholar 

  5. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five year perspective. Int J Obes 1989; 13 (Suppl 2): 39–46.

    Google Scholar 

  6. Perri MG. Improving maintenance of weight loss following treatment by diet and lifestyle modification. In: Wadden TA, Vanitallie TB, eds. Treatment of the Seriously Obese Patient. Guilford, New York, 1992, pp. 456–477

    Google Scholar 

  7. Wilson GT. Behavioral treatment of obesity: thirty years and counting. Adv Behav Res Ther 1993; 16: 31–75.

    Article  CAS  Google Scholar 

  8. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity in mice. Diabeltologia 1979; 14: 141–148.

    Article  Google Scholar 

  9. Ryan DH, Kaiser P, Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res 1995; 3 (Suppl 4): 553S–559S.

    Article  CAS  Google Scholar 

  10. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes 1993; 17 (Suppl 1): S73–S78.

    Google Scholar 

  11. Toubro S, Astrup AV, Breum 1., Quaade F. Safety and efficacy of long-term treatment with ephedrine, caffeine, and an ephedrine/caffeine mixture. Int J Obes 1993; 17 (Suppl 1): S69–S72.

    Google Scholar 

  12. Dulloo AG. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes 1993; 17 (Suppl 1): S35–S40.

    CAS  Google Scholar 

  13. Arner P. Adenosine, prostaglandins and phosphodiesterase as targeted for obesity pharmacotherapy. Int J Obes 1993; 17 (Suppl 1): 557–S59.

    Google Scholar 

  14. Drent ML, van der Veen EA. First clinical studies with orlistat: a short review. Obesity Res 1995; 3 (Suppl 4): 623S–625S.

    Article  CAS  Google Scholar 

  15. James WP, Avenell A, Broam J, Whitehead J. A one year trial to assess the value of orlistat in the management of obesity. Int J Obesity 1997; 21 (Suppl 3): S24–S30.

    CAS  Google Scholar 

  16. Berger M. Pharmacological treatment of obesity: digestion and absorption inhibitors-clinical perspective. Am J Clin Nutr 1992; 55: 318S–319S.

    CAS  Google Scholar 

  17. Bray GA. Pharmacologic treatment of obesity: symposium overview. Obes Res 1995; 3 (Suppl 4): 415S–417S.

    Article  Google Scholar 

  18. Pi-Sunyer X. Guidelines for the approval and use of obesity drugs. Obes Res 1995; 3: 473–478.

    Article  Google Scholar 

  19. Kissebach AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982; 54: 254–260.

    Article  Google Scholar 

  20. Scoville BA. Review of amphetamine-like drugs by the Food and Drug Administration. In: Vol. II, Bray GA, eds. Obesity in Perspective. Fogarty International Center for Advanced Studies in the Health Sciences, Series on Preventive Medicine, Washington, DC, US Government Printing Office, 1976, pp. 441–443.

    Google Scholar 

  21. Silverstone T. Appetite suppressants: a review. Drugs 1992; 43: 820–836.

    Article  CAS  Google Scholar 

  22. Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60: 647–657.

    CAS  Google Scholar 

  23. Goldstein DJ, Rampey AH Jr, RobackPJ, Wilson MG, Hamilton SH, Sayler ME, Tollefson GD. Efficacy and safety of long-term fluoxetine treatment of obesity-maximizing success. Obes Res 1995; 3 (Suppl 4): 481S–490S.

    Article  CAS  Google Scholar 

  24. Greenway FL. Clinical studies with phenylpropanolamine: a metaanalysis. Am J Clin Nutr 1992; 55 (1 Suppl): 203S–205S.

    CAS  Google Scholar 

  25. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984; 144: 1143–1148.

    Article  CAS  Google Scholar 

  26. Weintraub M. Long-term weight control: The National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992; 51: 581–646.

    Article  CAS  Google Scholar 

  27. Atkinson RL, Blank RC, Schumacher D, Dhurandhar NV, Ritch DL. Long term drug treatment of obesity in a private practice setting. Obes Res 1997; 5: 578–586.

    Article  CAS  Google Scholar 

  28. Hartley GG, Nicol S, Halstenson C, Khan M, Pheley A. Phentermine, fenfluramine, diet, behavior modification, and exercise for treatment of obesity. Obes Res 1995; 3 (Suppl 3): 340s.

    Google Scholar 

  29. Dhurandhar NV, Blank RC, Schumacher D, Ritch DL, Chan E, Reig TS, et al. Combination drug treatment of obesity in women of different ages. Obes Res 1995; 3 (Suppl 3): 341S.

    Google Scholar 

  30. Dhurandhar NV, Blank RC, Schumacher D, Ritch DL, Chan E, Reig TS, et al. Racial differences in response to combination drug treatment of obesity. Obes Res 1995; 3 (Suppl 3): 405s.

    Google Scholar 

  31. Dhurandhar NV, Atkinson RL. Comparison of serotonin agonists in combination with phentermine for treatment of obesity. FASEB J 1996; 10: A561

    Google Scholar 

  32. Foster GD, Wadden TA, Vogt RA, Brewer G. What is a reasonable weight loss? Patients’ expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997; 65 (1): 79–85

    Article  CAS  Google Scholar 

  33. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70: 537–541.

    Article  CAS  Google Scholar 

  34. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609–616.

    Article  CAS  Google Scholar 

  35. Manson JE, Faich GA. Pharmacotherapy for obesity-do the benefits outweigh the risks? N Engl J Med 1996; 335: 659–660.

    Article  CAS  Google Scholar 

  36. Dhurandhar NV, Atkinson RL. Appetite-suppressant drugs and primary pulmonary hypertension. N Engl J Med 1997; 36: 511.

    Google Scholar 

  37. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N EngL J Med 1997; 337: 581–588.

    Article  CAS  Google Scholar 

  38. Cannistra LB, Davis SM, Bauman AG. Valvular heart disease associated with dexfenfluramine. N Engl J Med 1997; 337: 636.

    Article  CAS  Google Scholar 

  39. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 635.

    Article  CAS  Google Scholar 

  40. Kurz X, Van Ezmen A. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 1772–1773.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Richard L. Atkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lilly Research Laboratories, Indiana University School of Medicine, Indianapolis, IN, USA

    David J. Goldstein MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Atkinson, R.L. (1999). Practical Aspects of Obesity Treatments. In: Goldstein, D.J. (eds) The Management of Eating Disorders and Obesity. Nutrition ◊ and ◊ Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-694-2_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-694-2_17

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6761-2

  • Online ISBN: 978-1-59259-694-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation